Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma



Summary

Real-world data on idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapy for multiple myeloma reveals distinct immune correlates associated with efficacy. While both products target BCMA, key differences in CAR-T cell expansion, persistence, and phenotype influence patient outcomes. Studies indicate that early CAR-T expansion and persistence are linked to deeper and more durable responses. Specific T-cell subsets, such as memory and effector cells, also play a role in treatment success. Understanding these immune correlates is crucial for optimizing patient selection, predicting response, and potentially developing strategies to enhance CAR-T efficacy in this challenging patient population.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!